Valicenti Advisory Services Inc. Has $5.84 Million Position in Zoetis Inc. (NYSE:ZTS)

Valicenti Advisory Services Inc. lifted its stake in Zoetis Inc. (NYSE:ZTS) by 0.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 29,906 shares of the company’s stock after purchasing an additional 272 shares during the period. Zoetis accounts for 1.5% of Valicenti Advisory Services Inc.’s portfolio, making the stock its 26th largest position. Valicenti Advisory Services Inc.’s holdings in Zoetis were worth $5,843,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Bogart Wealth LLC boosted its stake in Zoetis by 1.2% in the third quarter. Bogart Wealth LLC now owns 32,561 shares of the company’s stock valued at $6,362,000 after acquiring an additional 372 shares during the last quarter. Lafayette Investments Inc. boosted its stake in Zoetis by 4.6% in the third quarter. Lafayette Investments Inc. now owns 1,716 shares of the company’s stock valued at $335,000 after acquiring an additional 76 shares during the last quarter. Grimes & Company Inc. bought a new position in Zoetis in the third quarter valued at approximately $263,000. Cherry Creek Investment Advisors Inc. boosted its stake in Zoetis by 2.0% in the third quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock valued at $590,000 after acquiring an additional 58 shares during the last quarter. Finally, Romano Brothers AND Company boosted its stake in Zoetis by 2.3% in the third quarter. Romano Brothers AND Company now owns 3,391 shares of the company’s stock valued at $663,000 after acquiring an additional 75 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Down 4.0 %

NYSE:ZTS opened at $181.52 on Friday. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The stock has a market cap of $82.24 billion, a price-to-earnings ratio of 35.52, a PEG ratio of 2.94 and a beta of 0.89. The stock has a 50-day moving average price of $189.23 and a two-hundred day moving average price of $177.58.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The firm had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The company’s revenue was up 8.3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.41 earnings per share. As a group, equities analysts expect that Zoetis Inc. will post 5.83 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 annualized dividend and a dividend yield of 0.95%. Zoetis’s dividend payout ratio is currently 33.86%.

Analyst Ratings Changes

ZTS has been the topic of a number of recent research reports. JPMorgan Chase & Co. raised their price objective on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Piper Sandler raised their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Stifel Nicolaus lifted their price target on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Finally, BTIG Research boosted their price target on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.